User profiles for Penny L. Moore
 | Penny MooreProfessor & Head Virology and Immunology, Wits University and NICD Verified email at nicd.ac.za Cited by 15293 |
SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma
SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains
substitutions in two immunodominant domains of the spike protein. Here, we show that …
substitutions in two immunodominant domains of the spike protein. Here, we show that …
Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant
Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the …
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the …
The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection
An understanding of how broadly neutralizing activity develops in HIV-1-infected individuals
is needed to guide vaccine design and immunization strategies. Here we used a large …
is needed to guide vaccine design and immunization strategies. Here we used a large …
Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape
Neutralizing antibodies are likely to play a crucial part in a preventative HIV-1 vaccine.
Although efforts to elicit broadly cross-neutralizing (BCN) antibodies by vaccination have been …
Although efforts to elicit broadly cross-neutralizing (BCN) antibodies by vaccination have been …
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1
PL Moore, ET Crooks, L Porter, P Zhu… - Journal of …, 2006 - Am Soc Microbiol
Human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies are thought be
distinguished from nonneutralizing antibodies by their ability to recognize functional gp120/gp41 …
distinguished from nonneutralizing antibodies by their ability to recognize functional gp120/gp41 …
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B.1.1.529),
first identified in Botswana and South Africa, may compromise vaccine effectiveness and …
first identified in Botswana and South Africa, may compromise vaccine effectiveness and …
T cell responses to SARS-CoV-2 spike cross-recognize Omicron
The SARS-CoV-2 Omicron variant (B.1.1.529) has multiple spike protein mutations 1 , 2 that
contribute to viral escape from antibody neutralization 3 , 4 , 5 – 6 and reduce vaccine …
contribute to viral escape from antibody neutralization 3 , 4 , 5 – 6 and reduce vaccine …
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection
We previously showed that HIV-1 subtype C viruses elicit potent but highly type-specific
neutralizing antibodies (nAb) within the first year of infection. In order to determine the specificity …
neutralizing antibodies (nAb) within the first year of infection. In order to determine the specificity …
[HTML][HTML] SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
The emergence of SARS-CoV-2 Omicron, first identified in Botswana and South Africa, may
compromise vaccine effectiveness and the ability of antibodies triggered by previous …
compromise vaccine effectiveness and the ability of antibodies triggered by previous …
